Tapan M. Kadia MD

Hematologic Oncology

Professor, Leukemia Department

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 713-563-7746

Dr. Kadia is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kadia's full profile Already have an account?

Summary

I am currently Professor in the Department of Leukemia at MD Anderson Cancer Center, focused on high-level clinical research and compassionate patient care, delivering innovative treatments to patients with leukemia.

I have worked to expand and effectively communicate knowledge in diagnosis, prognosis, and new treatments through publications and educational initiatives for trainees and practicing physicians. I have led numerous clinical trials that have helped changed the standard of care for patients with leukemia. I am primary investigator on numerous ongoing studies, with a focus on treatments for patients with acute myeloid leukemia (AML), T-cell leukemias, and bone marrow failure syndromes, aiming to discover new approaches in areas of unmet need.

Education has been a major passion and commitment of mine since being on the faculty. I serve as the Program Director of the Leukemia Fellowship, directly mentoring dozens of fellows over the years, helping them navigate their journey through specialty training on the way to build balanced and productive careers in academic and clinical medicine. I also serve as a co-chair of the MD Anderson Board Review course, which has served to help educate fellows and practicing physicians on hematology and cancer care in preparation for board certification for over two decades.

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Baylor College of MedicineResidency, Internal Medicine, 2001 - 2005
Rutgers Robert Wood Johnson Medical SchoolClass of 2001

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
GA State Medical License 2026 - 2028
TN State Medical License 2026 - 2028
TX State Medical License 2004 - 2028
AZ State Medical License 2026 - 2027
MS State Medical License 2026 - 2027
OK State Medical License 2020 - 2027
AL State Medical License 2026 - 2026
American Board of Internal Medicine Hematology
Join now to see all

Awards, Honors, & Recognition

Gerald Bodey Excellence in Education MD Anderson Cancer Center
CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015

Clinical Trials

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies Start of enrollment: 2010 Jun 08
COMPLETED
PHASE1
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
TERMINATED
PHASE2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2012 Feb 07
RECRUITING
PHASE2

Publications & Presentations

PubMed

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.
Aziz Farhat, Georgina El Hajjar, Hagop Kantarjian, Koji Sasaki, Nicholas J Short
Cancer. 2026-08-15
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.
Darren Lee, Yazan Abu-Shihab, Kate Plas, Deedra Nicolet, Krzysztof Mrózek
Leukemia. 2026-08-01
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, Wei Ying Jen, Alex Bataller
Journal of Clinical Oncology. 2026-08-01

Journal Articles

Response Kinetics and Factors Predicting Survival in Core-Binding Factor Leukemia
Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Nature

Abstracts/Posters

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Di...
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Less Is More
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Authored Content

A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017

Press Mentions

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid MalignancesDecember 8th, 2025
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025November 4th, 2025
Naveen Pemmaraju: MECOM Fusion Partner and Bone Marrow Blast Percentage Influence Outcomes of Patients with MECOMSeptember 24th, 2025